Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
  • A61L17/06—At least partially resorbable materials
  • A61L17/10—At least partially resorbable materials containing macromolecular materials
  • A61L17/105—Polyesters not covered by A61L17/12
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
  • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
  • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
  • A61B17/06166—Sutures
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/505—Stabilizers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
  • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
  • A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/143—Stabilizers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/148—Materials at least partially resorbable by the body

Definitions

• composition Composition, body, thread, medical kit and medical product with improved degradation profile
• the invention relates to a composition comprising polydioxanone and / or a copolymer thereof, a shaped article comprising the composition, a thread comprising the composition, a medical kit comprising the composition and a medical product comprising the composition.
• Polydioxanone is a resorbable, synthetic polymer with numerous medical uses.
• polydioxanone Compared with polyglycolide and polylactide, polydioxanone has the fundamental advantage of greater flexibility (lower flexural rigidity), which is why monofilament surgical suture materials are also manufactured and used.
• polydioxanone In contrast to polyglycolide and its copolymers, polydioxanone additionally shows a slower hydrolytic degradation, which is of particular advantage in particular with indications with a delayed wound healing process.
• suture materials based on polydioxanone are used, which are dyed to improve their handling properties (visualization in the operating field) by means of a dye.
• Such sutures are, for example, under the names Mono Plus ® (B.Braun Aesculap), PDS II ® (Ethicon) or vetsu- ture PDX ® (VETSUTURE) commercially available.
• PDS II the dyed suture materials have a higher resistance to degradation than the undyed suture materials, which is also desirable depending on the indication.
• compositions having the features of independent claim 1 Preferred embodiments of the composition are the subject matter of dependent claims 2 to 12. Furthermore, the subject matter of the invention is a shaped body having the features of claim 13. A preferred embodiment of the shaped body is reproduced in claim 14. A further subject of the invention is a thread with the features of claim 15. A preferred embodiment of the thread is the subject of claim 16. Further subject matters relate to a medical kit with the features of claim 17 and a medical product having the features of claim 18.
• the composition proposed according to the invention comprises polydioxanone (poly-para-dioxanone or PDO) and / or a copolymer thereof. In addition, the composition comprises at least one carboxylic acid salt.
• copolymer is to be understood as meaning a polymer which, besides para-dioxanone, is formed from at least one further monomer component
• copolymer may therefore include bipolymers, tripolymers, tetrapolymers, in particular with random or segmented distribution of the monomers, or the like.
• the term "at least one carboxylic acid salt” is to be understood as meaning a carboxylic acid salt or a plurality, that is, two or more different carboxylic acid salts.
• the composition according to the invention is distinguished by a slowed-down or delayed, preferably hydrolysis-based degradation profile (degradation profile).
• degradation profile a slowed-down or delayed, preferably hydrolysis-based degradation profile (degradation profile).
• This is presumably due to an increased formation of smaller crystals or smaller spherulites in the composition or the polymer (PDO and / or copolymer thereof), as a result of which a more homogeneous and overall accelerated crystallization takes place.
• the aqueous degradation medium seems to be able to penetrate the composition only more slowly and spatially more limited, which slows down the degradation rate becomes.
• the at least one carboxylic acid salt can also be understood as a nucleating agent.
• composition proposed according to the invention is also suitable as starting material for the production of shaped articles, in particular in the form of medical products such as surgical threads or sutures, guide rails, nets, stents and stent grafts or injection-molded articles such as staples, clips or vascular occlusion plugs, with a delayed degradation behavior.
• filaments prepared from the composition according to the invention even after several weeks of storage in Sörensen buffer, showed Knot Pull Tensile Strength (KPTS) and Linear Tensile Strength (LTS), which were each significantly higher than for filaments which had no carboxylic acid salt, this difference being greater in undyed compared to colored threads.
• KPTS Knot Pull Tensile Strength
• LTS Linear Tensile Strength
• the composition according to the invention is furthermore distinguished by good handling properties, in particular processing properties.
• the composition has a residual monomer content and an inherent viscosity or molecular weight which are comparable to the residual monomer content and the inherent viscosity or molecular weight of not containing a carboxylic acid salt additized polydioxanone.
• no significant degradation of the polymer is induced by the at least one carboxylic acid salt during the processing of the composition, for example into a thread, with particular advantage. This is shown by For example, at the nozzle pressures during extrusion, which remained at the same level.
• a subsequent stretching does not lead to any thread breakage.
• the stretching can be carried out without appreciable deviations in the draw ratios.
• the presence of the at least one carboxylic acid salt in the composition does not or does not significantly affect the mechanical integrity of products made from the composition, such as filaments, for example, and promotes processability.
• a thread is formed from the composition, then this is characterized with particular advantage by a smooth surface and an optimized under medical aspects Biegepatentedfheit. The smooth surface with a low coefficient of friction facilitates in particular the atraumatic pulling of the thread through the fabric.
• the at least one carboxylic acid salt in a preferred embodiment is a metal salt, preferably alkali metal and / or alkaline earth metal salt, of a carboxylic acid.
• the at least one carboxylic acid salt is preferably selected from the group consisting of barium salt of a carboxylic acid, magnesium salt of a carboxylic acid, calcium salt of a carboxylic acid, strontium salt of a carboxylic acid and mixtures thereof.
• the at least one carboxylic acid salt is a colorless or non-coloring carboxylic acid salt.
• a colored or coloring carboxylic acid salt may also be considered.
• the at least one carboxylic acid salt may further be the salt of an aliphatic and / or aromatic carboxylic acid.
• the at least one carboxylic acid salt may be the salt of a saturated or unsaturated, in particular double and / or triple bond-containing, carboxylic acid.
• the at least one carboxylic acid salt may be the salt of a branched or unbranched carboxylic acid.
• the at least one carboxylic acid salt is the salt of an aliphatic, in particular saturated, and preferably unbranched carboxylic acid.
• the at least one carboxylic acid salt may in further embodiments be selected from the group consisting of fatty acid salt, amino acid salt, oxalic acid salt, salicylic acid salt, benzoic acid salt, nicotinic acid salt, resin acid salt and mixtures thereof.
• the at least one carboxylic acid salt is a fatty acid salt, preferably a salt of a saturated and in particular unbranched fatty acid.
• the fatty acid may in principle be a lower fatty acid, ie a fatty acid having 1 to 7 carbon atoms, middle fatty acid, ie a fatty acid having 8 to 12 carbon atoms, and / or a higher fatty acid, ie a fatty acid having more than 12 carbon atoms
• the fatty acid salt can be selected from the group consisting of formic acid salt, acetic acid salt, propionic acid salt, butyric acid salt, isobutyric acid salt, valeric acid salt, isovaleric acid salt, capronic acid salt, oenanthic acid salt, caprylic acid salt, pelargonic acid salt, capric acid salt, undecanoic acid salt, lauric acid salt, tridecanoic acid salt, myristic acid salt, pentadecanoic acid salt , Palmitic acid salt, oleic acid salt, linoleic acid salt, linolenic acid salt, magaric acid salt, stea
• the at least one carboxylic acid salt is selected from the group consisting of lauric acid salt, myristic acid salt, palmitic acid salt, magaric acid salt, stearic acid salt, and mixtures thereof.
• the at least one carboxylic acid salt is an alkaline earth metal stearate, in particular selected from the group consisting of barium stearate, magnesium stearate, calcium steate, strontium stearate and mixtures thereof.
• Calcium stearate is preferred according to the invention.
• the at least one carboxylic acid salt may have a content of 0.1 to 10% by weight, in particular 0.2 to 8% by weight, preferably 0.4 to 5% by weight, based on the total weight of the composition.
• a carboxylic acid salt content of from 0.4 to 5% by weight is suitable in particular for delaying or slowing down a degradation of the composition which is preferably based on hydrolysis.
• a Carboxylic acid content of 0.1 to 0.4 wt .-%, based on the total weight of the composition be advantageous.
• the at least one carboxylic acid salt is contained in the paradioxanone and / or the copolymer.
• the polydioxanone and / or the copolymer thereof is provided with the at least one carboxylic acid salt, additized or compounded.
• the at least one carboxylic acid salt is distributed homogeneously or substantially homogeneously within the composition, in particular within the polydioxanone and / or the copolymer thereof. In other words, it is preferred that there are no significant local concentration differences and / or agglomerates with respect to the at least one carboxylic acid salt.
• the copolymer may be a static copolymer, segmented copolymer or block copolymer.
• the copolymer is formed mainly from para-dioxanone.
• the para-dioxanone may have a content of at least 55%, in particular from 60 to 98%, preferably from 70 to 95%, based on the total number of monomer units present in the copolymer.
• the copolymer is preferably formed from at least one further monomer component, preferably a resorbable monomer component.
• the monomer component may be selected from the group consisting of glycolide, lactide, ⁇ -caprolactone, trimethylene carbonate, hydroxybutyrate, in particular 3-hydroxybutyrate and / or 4-hydroxybutyrate, and combinations thereof.
• the copolymer may be formed in addition to para-dioxanone of ethylene glycol and / or diethylene glycol.
• the copolymer has polyethylene glycol units, in particular in the form of blocks.
• the polydioxanone or copolymer thereof preferably forms the main constituent of the composition.
• the term "main constituent" is to be understood here as meaning a polydioxanone or copolymer fraction of at least 50% by weight, based on the total weight of the composition.
• the polydioxanone or copolymer thereof in a further embodiment, a proportion of 50 to 99.9 wt .-%, preferably 65 to 99.8 wt .-%, particularly preferably 80 to 99.8 wt .-%, based on the total weight of the composition.
• the composition may further comprise additives.
• Suitable additives may be selected from the group consisting of fillers, in particular inorganic fillers, X-ray contrast agents, antimicrobially active compounds, polymers, chemical and / or physical blowing agents and mixtures of these additives.
• suitable fillers may be selected from the group consisting of calcium carbonate, .beta.-tricalcium phosphate, calcium sulfate, hydroxyapatite and mixtures thereof.
• antimicrobial compounds may be selected from the group consisting of guanidines, especially polyhexamethylene biguanide (PHMB), metals or metal salts such as silver or silver salts, antibiotics and mixtures thereof.
• Chemical and / or physical blowing agents may generally be of interest for producing foam structures, for example, with regard to injection molding applications of the composition. Suitable physical blowing agents are, in particular, blowing gases such as, for example, nitrous oxide, carbon dioxide, oxygen, nitrogen or the like.
• Suitable chemical blowing agents are mixtures of carbonate and bicarbonate salts, preferably of alkali and alkaline earth metals, in particular in combination with citric acid and / or thereof Salts (passive chemical blowing agents), dar.
• X-ray contrast agents such as, for example, barium sulfate are suitable as contrast agents.
• the composition has as an additive a resorbable or at least water-soluble homopolymer, copolymer or terpolymer which differs from polydioxanone (PDO) and preferably its copolymer.
• PDO polydioxanone
• the composition can be present in particular as a compatible or incompatible polymer blend (blend).
• composition in addition to the polydioxanone and / or copolymer thereof has no further polymers or is formed from no further polymer.
• the composition consists of polydioxanone or a copolymer thereof and the at least one carboxylic acid salt and optionally one or more additives.
• suitable additives reference is made to the additives described in the previous embodiments. In particular, the composition of any of the preceding Embodiments described material combinations or mixtures exist.
• the composition can, in particular after a shaping step such as, for example, extrusion, and in particular after a subsequent aftertreatment such as, for example, a residual monomer content of 0.5 to 6%, in particular of at most 3%, preferably of at most 2%, especially preferably of not more than 1.2%.
• a shaping step such as, for example, extrusion
• a subsequent aftertreatment such as, for example, a residual monomer content of 0.5 to 6%, in particular of at most 3%, preferably of at most 2%, especially preferably of not more than 1.2%.
• the composition may have an inherent viscosity of from 0.7 to 2.2 dl / g, in particular from 1.0 to 2.0 dl / g, preferably from 1.2 to 1.8 dl / g.
• the viscosity values relate to the measurement of the viscosity of a hexafluoroisopropanol (HFIP) solution which contains the composition in a concentration of 0.5% by weight, at a temperature of 30 ° C. by means of an Oa viscometer.
• HFIP hexafluoroisopropanol
• a second aspect of the invention relates to a shaped article comprising a composition according to the present invention or consisting of such a composition.
• the shaped body may be a half-part, finished part or end product.
• the shaped body may have anchoring structures on its surface for anchoring in human or animal tissue, in particular in the form of Barbs or barbs.
• the anchoring structures are preferably formed as incisions in the shaped body surface
• the incisions and / or punches are preferably made in the unstretched state of the shaped body, and subsequent stretching results in the anchoring structures being particularly advantageous and in particular exhibiting particular advantages
• the anchoring structures allow in particular the performance of wound closures and / or bone and / or organ fixations.
• a third aspect of the invention relates to a thread, in particular a medical thread, preferably surgical thread or a surgical suture.
• the suture comprises a composition according to the present invention or consists of such a composition.
• the yarn in addition to the polydioxanone and / or copolymer thereof, has no further polymers or is formed from no further polymer.
• the thread may be formed as monofilament, pseudomonofiler or multifilament, in particular braided, thread.
• the thread may have anchoring structures on its surface for anchoring in human or animal tissue, in particular in the form of barbs or barbs, etc.
• the anchoring structures are preferably formed as incisions in the thread surface Alternatively, the anchoring structures can also be formed by punching. The incisions and / or punches (from which the anchoring structures form) are preferably made in the unstretched state of the thread.
• the anchoring structures allow, in particular, the performance of wound closures and / or bone and / or organ fixations.
• “Hiding (stretching)” is generally understood in textile technology as a process step in the production of man-made fibers, in which the polymer chains present in the spun yarn are generally disordered and knit-shaped, generally with an increase in crystallization, by stretching the unstretched spun yarn over a plurality of fibers
• elements of the drafting system may be heatable to heat the wire over its glass transition point and to draw it in that condition. When drawn, a diameter decrease usually takes place approximately by the factor of root of the draw ratio The strength of the drawn thread is usually several times higher and its elongation at break is usually many times lower than that of the spun thread The drawing can be done in one or in m more stages. At the end you can either fix or relax.
• the thread may have a circular or non-circular, for example oval or polygonal, cross-section.
• the thread may have a thread thickness which is selected from the group consisting of USP 1 1 -0 (0.010-0.019 mm), USP 10-0 (0.020-0.029 mm), USP 9-0 (0.030-0.039 mm), USP 8-0 (0.040-0.049 mm), USP 7-0 (0.050-0.069 mm), USP 6-0 (0.070-0.099 mm), USP 5-0 (0.100-0, 149 mm), USP 4-0 (0.150-0, 199 mm), USP 3-0 (0.200-0.249 mm), USP 2-0 (0.300-0.339 mm), USP 0 (0.350-0.399 mm), USP 1 (0.400-0.499 mm), USP 2 (0.500-0.599 mm), USP 3/4 (0.600-0.699 mm) and USP 5 (0.700-0.799 mm). (Table for Synthetic Absorbable Sutures of USP 35)
• the thread has a thread thickness between USP 6-0 and USP 2.
• the thread may have a core-shell structure in another embodiment.
• the composition may be contained in the core and / or sheath, or the core and / or sheath may consist of the composition.
• the composition is contained only in the sheath or only the sheath of the thread consists of the composition. In this way, the mechanical integrity of the thread core remains completely untouched.
• the thread has an "islands-in-the-sea" structure, with the “sea” regions of the thread preferably containing or consisting of the composition.
• the thread in particular with regard to the composition, the polydioxanone and / or copolymer thereof, the at least one carboxylic acid salt and / or any additives, reference is likewise made in full to the previous description.
• the invention also relates to a medical, in particular surgical, set comprising at least one, in particular one, needle and at least one, in particular, thread according to the present invention.
• the invention relates to a medical product comprising or consisting of a composition according to the present invention.
• the product may comprise at least one thread, in particular a plurality of threads (ie, two or more threads) according to the present invention, or consist of at least one such thread or a plurality of such threads.
• the medical product is preferably a surgical implant.
• the medical product is preferably a textile implant, in particular a two-dimensional or three-dimensional textile implant.
• the medical product can be designed as a flat structure, in particular a textile fabric, or as a hollow body replacement structure, in particular a textile hollow body replacement structure.
• the hollow body replacement structure is furthermore preferably tubular, tubular or cylindrical.
• the medical product has a textile structure, which is preferably selected from the group consisting of woven, knitted fabric, in particular warp knit, braid, knitted fabric and combinations thereof.
• the medical product may have a non-woven structure which is preferably selected from the group consisting of spunbonded nonwoven, spunbond nonwoven, nonwoven spunbond, meltblown nonwoven, electroformed nonwoven, or spunbond nonwoven.
• the medical product may also have a non-textile structure and be formed, for example, as a film, membrane, in particular capillary membrane, hose or the like.
• the medical product can furthermore be designed as a network, preferably a medical network, particularly preferably a surgical network.
• the medical product may be selected from the group consisting of hernia mesh, prolapse mesh and incontinence mesh.
• the medical product is designed as a prosthesis, in particular an endoprosthesis such as, for example, a vascular prosthesis, stent or stent-graft.
• the medical product can be a surgical staple, a surgical clip, a surgical anchor, in particular a bone anchor, or a vascular occlusion plug.
• Example Part The monofilaments listed in the Examples section are in most cases sorted over the diameter compared to the USP classes, such as the industrial standard.
• Temperature extruder zone 1 140 ° C
• Temperature extruder Zone 2 160 ° C
• the spun yarn had a diameter of 0.686 mm and a monomer content of 1.8%.
• the die pressure in the extrusion was 63 bar and the inherent viscosity of the spun yarn was 1.54 dl / g.
• the stretching was carried out on a line consisting of delivery blanket, drawing furnace 1, septet 1, drawing furnace 2, septet 2 and winder.
• the temperature of the first drafting oven was 80 ° C and that of the second drafting oven was 95 ° C
• the main draw ratio in stage 1 was 5.3 and the total draw ratio was 5.6.
• the draw point (neck-point) was stable on the Danielgalette and there were no thread breaks.
• the diameter of the drawn yarn 1 -1 was 0.297 mm ⁇ 0.003 mm and the yarn surface was absolutely smooth.
• the monomer content was 0.6 mol%.
• the mechanical properties of the monofilament are shown in Table 1.
• the spun yarn had a diameter of 0.684 mm and a monomer content of 2.0%.
• the die pressure in the extrusion was 61 bar and the inherent viscosity of the spun yarn was 1.52 dl / g.
• the stretching was started with the parameters from Example 1. It was found that the draw point from the delivery galette wandered all the way into the drafting furnace 1, but from time to time also looked out of the furnace again, which is an indication of a thread tension that is not constant over time. The surface of the monofilament 2-1 thus obtained had rough spots, and diameter irregularities were clearly felt. The diameter was 0.296 mm ⁇ 0.01 1 mm. A thread break did not occur under these settings.
• the main draw ratio in Stage 1 had to be increased to 5.9 and the total draw ratio to 6.6.
• the diameter of the monofilament 2-2 was 0.277 mm ⁇ 0.005 mm.
• Increasing the draw ratio increased the ovality of the monofilament from 0.003 mm to 0.021 mm.
• a reduction in the draw ratio did not improve this situation as long as the draw point was kept on the delivery roll.
• the draw point again began to migrate to form rough spots and diameter variations.
• the calcium stearate CPR-2-V from Greven (Germany) and the PDO polymer from Example 1 were used.
• the additive (0.7 g) was added to 1000 g of polymer and then distributed as homogeneously as possible with shaking and tumbling , Subsequently, as described in Example 1 dried and extruded.
• the spun yarn had a diameter of 0.684 mm and a monomer content of 1.8%.
• the die pressure in the extrusion was 61 bar and the inherent viscosity of the filament was 1.52 dl / g. This shows that no degradation of the polymer took place in the extruder due to the additive.
• Drawing and aftertreatment were carried out under the conditions of Example 1. There were no yarn breaks and the draw point was stable on the feed roll.
• the diameter of the drawn yarn 3-1 was 0.296 mm ⁇ 0.004 mm.
• the thread surface was absolutely smooth and felt in comparison to Example 1 a little softer, which may be due to reduced surface friction by the addition of fatty acid salt.
• the monomer content was 0.5 mol%.
• the mechanical properties of monofilament 3-1 are shown in Table 1.
• the spun yarn had a diameter of 0.684 mm and a monomer content of 1.7%.
• the die pressure in the extrusion was 62 bar and the inherent viscosity of the spun yarn was 1.50 dl / g. This shows that even by the higher concentration of additive no increased degradation of the polymer took place in the extruder.
• Drawing and aftertreatment were carried out under the conditions of Example 1. There were no yarn breaks and the draw point was stable on the feed roll.
• the diameter of the drawn yarn 3-1 was 0.296 mm ⁇ 0.003 mm.
• the thread surface was absolute Lut smoothed and felt softer compared to Example 1, probably due to reduced surface friction due to the addition of fatty acid salt.
• the monomer content was 0.6 mol%.
• the mechanical properties of monofilament 4-1 are shown in Table 1.
• Example 2 1000 g of the unstained polymer from Example 2 were mixed with 0.7 g of calcium stearate as described in Example 3 and extruded.
• the spun yarn had a diameter of 0.685 mm and a monomer content of 1.8%.
• the die pressure in the extrusion was 59 bar and the inherent viscosity of the spun yarn was 1.50 dl / g.
• Example 2 Surprisingly, in comparison to the non-additized, uncolored PDO from Example 2, it was found that the draw point under the standard drawing conditions of Example 1 was constant on the delivery roller, so that an increase in the draw ratio was not necessary. Also, in contrast to Example 2-1, no rough spots and diameter variations occurred and, in contrast to Example 2-2, no thread breaks and no appreciable ovality. Experimentally, the draw ratio in stage 1 was lowered from 5.3 to 5. 1. Thanks to the addition of calcium stearate, however, the draw point remained stable on the delivery roll. The diameter of the drawn yarn 5-1 was 0.295 mm ⁇ 0.004 mm. The thread surface was absolutely smooth and felt somewhat softer compared to Example 2, probably due to reduced surface friction due to the addition of fatty acid salt. After a post-treatment step for fixation and demonomerization, the monomer content was 0.5 mol%. The mechanical properties of the monofilament 5-1 are shown in Table 1. Example 6
• the spun yarn had a diameter of 0.684 mm and a monomer content of 1.9%.
• the die pressure in the extrusion was 58 bar and the inherent viscosity of the spun yarn was 1.48 dl / g.
• Example 5 it was also surprising here that the draw point under the standard drawing conditions of Example 1 was constant on the delivery roll, so that an increase in the draw ratio was not necessary. Also, in contrast to Example 2-1, no rough spots and diameter variations occurred and, in contrast to Example 2-2, no thread breaks and no appreciable ovality. As an experiment, the draw ratio in stage 1 was also reduced from 5.3 to 5.0 here. Thanks to the increased addition of calcium stearate, however, the draw point remained stable on the delivery roll.
• the diameter of the drawn yarn 6-1 was 0.295 mm ⁇ 0.003 mm.
• the thread surface was absolutely smooth and felt softer compared to Example 2, probably due to reduced surface friction due to the increased addition of fatty acid salt.
• the monomer content was 0.6 mol%.
• the mechanical properties of monofilament 6-1 are shown in Table 1.
• Example 5 The preparation of the monofilament and the use of the materials required for this corresponded to Example 5, but using 10.0 g of calcium stearate based on 1000 g of PDO polymer.
• the spun yarn had a diameter of 0.685 mm and a monomer content of 1.7%.
• the die pressure in the extrusion was 63 bar and the inherent viscosity of the spun yarn was 1.52 dl / g.
• Example 5 it was also surprising here that the draw point under the standard drawing conditions of Example 1 was constant on the supply roll, so that an increase in the draw ratio was not necessary. Also, in contrast to Example 2-1, no rough spots and diameter variations occurred and, in contrast to Example 2-2, no thread breaks and no appreciable ovality. As an experiment, the draw ratio in stage 1 was also reduced from 5.3 to 5.0 here. Thanks to the increased addition of calcium stearate, however, the draw point remained stable on the delivery roll. There was also a tentative increase in the main draw ratio from 5.3 to 5.9 without yarn breakage, but with an increase in ovality. The diameter of the drawn yarn 7-1 was 0.294 mm ⁇ 0.003 mm.
• the thread surface was absolutely smooth and felt much softer compared to Example 2, which was probably due to reduced surface friction or reduced bending strength. is due to the increased addition of fatty acid salt.
• the monomer content was 0.5 mol%.
• the mechanical properties of monofilament 7-1 are shown in Table 1.
• Example 1 -1 essentially corresponds to commercially available, violet colored surgical suture materials such as the PDS II ® (Ethicon) or mono Plus ® (B.Braun Aesculap)
• PDS II ® Ethicon
• mono Plus ® B.Braun Aesculap
• Table 1 shows, the mechanical properties of undyed monofilaments without additive compared to violet Industrial Standard 1 -1 (v) unsatisfactory. Add to this the poor stretchability of 2-2 (u) and the frequent occurrence of thread breaks.
• This problem could be surprisingly solved by the addition of calcium stearate, whereby an increase in the knot-pull breaking strength compared to the industrial standard could also be achieved with violet polymer.
• Example 8 Example 8:
• Degradation means loss of mechanical strength in connection with resorbable materials.
• the flexural modulus of the monofilaments was determined on a flexural strength tester from Franckh (Germany) under standard conditions with a clamping length of 5 mm and a bending angle of 30 °.
• the flexural modulus was calculated from the bending stiffness by means of the moment of inertia of cylindrical bodies. The results are shown in Table 3:
• a PDO homopolymer with an inherent viscosity of 1.18 dl / g and a monomer content of 1.6 mol% was used.
• the polymer was dried for 20 h at a temperature of 80 ° C in a vacuum oven at 3 mbar and then transferred under nitrogen atmosphere in a granular bottle. This was attached via an adapter to the feed zone of a single-screw extruder with two heating zones.
• the extrusion parameters are as follows:
• Temperature extruder zone 1 130 ° C
• Temperature extruder Zone 2 160 ° C
• the spun yarn had a diameter of 1. 316 mm and a monomer content of 1.2%.
• the nozzle pressure during the extrusion was 75 bar.
• the stretching was carried out on a line consisting of delivery blanket, stretching furnace 1, septet 1, drawing furnace 2, septet 2 and winder.
• the temperature of the first draw furnace was 95 ° C and that of the second draw furnace 1 15 ° C, the main draw ratio in stage 1 was 5.3, as well as the total draw ratio, since in the 2nd stage only was fixed.
• the draw point (neck-point) was stable on the Danielgalette and there were no thread breaks.
• the diameter of the drawn yarn 8-1 was 0.595 mm ⁇ 0.005 mm and the yarn surface was absolutely smooth.
• the monomer content was 0.5 mol%.
• the mechanical properties and the retention of the knot-pull breaking strength after 4 weeks of degradation in the phosphate buffer at pH 7.4 at 37 ° C. of the monofilament are shown in Table 4.
• a PDO homopolymer having an inherent viscosity of 1.18 dl / g and a monomer content of 1.6 mol% was used.
• the polymer was vacuum dried for 20 hours at a temperature of 80 ° C dried cabinet at 3 mbar and then transferred under a nitrogen atmosphere in a granular bottle. This was attached via an adapter to the feed zone of a single-screw extruder with two heating zones.
• a spinning head with a spinning pump 4 x 0.25 ccm / U was flanged to the extruder.
• the extrusion was carried out in four digits.
• Temperature extruder zone 1 140 ° C
• Temperature extruder Zone 2 160 ° C
• the spun yarn had a diameter of 0.390 mm and a monomer content of 1.6%.
• the nozzle pressure during the extrusion was 73 bar.
• the stretching was carried out on a line consisting of delivery blanket, drawing furnace 1, septet 1, drawing furnace 2, septet 2 and winder.
• the temperature of the first drafting oven was 70 ° C and that of the second drafting oven was 80 ° C, the main draw ratio in stage 1 was 5.2, the total draw ratio was 5.3.
• the draw point (neck-point) was stable on the delivery godet and there was only one thread break at a total production of about 15,000 m.
• the diameter of the stretched Thread 9-1 was 0.172 mm ⁇ 0.003 mm and the thread surface was absolutely smooth.
• the monomer content was 0.6 mol%.
• the mechanical properties and the retention of the knot-pull breaking strength after 4 weeks of degradation in the phosphate buffer at pH 7.4 at 37 ° C. of the monofilament are shown in Table 4.
• Table 4 shows that the addition of carboxylic acid salts is feasible even with small and large USP starches and leads there as well to the excellent results, as they were surprisingly found at the average strength USP 3-0 (Examples 1-7). It should be noted that in monofilaments, both the knot breaking strength and the linear breaking strength, both related to the cross-sectional area of the monofilament, decrease with increasing diameter.
• Example 8-1 an undyed PDO monofilament of starch USP 2 additized with carboxylic acid salt, is somewhat above the violet, industrial standard in terms of strength and retention after a 4-week degradation.
• the extruded, unstretched strand from Example 2 was cut to a length of 30 cm.
• the strand was provided by means of a prototype cutting machine testweise with 50 cuts at a distance of 0.25 mm in the middle part of the strand, wherein the intersection angle to the thread surface was 25 ° and the depth of cut in relation to the diameter of the strand was 30%. The cuts were arranged offset by 120 ° to each other. Subsequently, it was planned to stretch the strand in a heated oven at 80 ° C discontinuously to a Rescueverstrecktex of 3.5 to 4.3, which barbs should form and straighten up.
• Example 13 While this was possible with the violet comparative material of Example 1 without any problems and without thread breakage, 8 of 10 samples broke during drawing. It was only by further reducing the draw ratio to 2.8 that no yarn breakage occurred in 10 out of 10 samples, but the cross-sectional strength was reduced by 45% over that of Example 1, which is unacceptable.
• Example 13
• the extruded, unstretched strand of Example 6 was cut to 30 cm in length. Subsequently, the strand was tested using a prototype cutting machine. wise provided with 50 cuts at a distance of 0.25 mm in the middle part of the strand, wherein the intersection angle to the thread surface was 25 ° and the depth of cut in relation to the diameter of the strand was 30%. The cuts were arranged offset by 120 ° to each other. In contrast to Example 10, the strand provided with the cuts could be stretched discontinuously in a heated oven at 80 ° C. without the occurrence of yarn breakage to a draw ratio of 3.5 to 4.3. The linear strength achieved was 5% above that of a yarn formed from the violet strand of Example 1.
• Example 14 Into the 1 .0 mm diameter rods of Example 14, incisions were made as described in Example 13 by means of the prototype cutting machine. Both chopsticks without and with 1, 0 wt .-% addition of carboxylic acid salt were used. The incised rods were stretched as described in Example 13. An alternative stretching method was to clamp the ends of the sliced rods into the clamps of a tensile tester and to heat the area between the clamps with hot air to 80 ° C and after a tempering time of 15 seconds move the clamps apart so that a draw ratio of 3.75 results. In both drawing methods, the breakage rate for the non-additized moldings was at least 75%, while the 1, 0% additized moldings did not break during the drawing. When stretched without breakage, the anchoring structures formed during stretching and posed.
• the shaped bodies having anchoring structures produced in this way can, for example, be used as resorbable, self-fixing bone pins, as suture anchors, as self-fixing closure plugs for vessels, but also as surgical suture material, without restricting the possibilities of use.
• planar anchoring structures formed and positioned in the center of the plate, with one part on the back and another part of the planar anchoring structures on the front of the platelets.
• the lateral, likewise punched out anchoring structures were given an additional shape by the stretching.
• the flat shaped bodies with anchoring structures produced in this way can, without restricting their use, serve, for example, to fix organs or bones according to the principle of a cable tie. Furthermore, for example, they can serve for lifting in cosmetic surgery by having either bidirectional anchoring structures or unidirectional anchoring structures with a stopper or a loop on a side opposite to the needle or the insertion tip and introduced linearly into the tissue. Quite generally, the anchorage mentioned in the example section can be used. Barb structures in addition to the process of punching by mechanical cutting, for example by means of blades, by laser cutting, by thermal cutting, for example by means of a heated over the melting point of the polymer wire, or produced by injection molding. The same applies to the anchoring structures mentioned in the general part of the description.
• the quality of the thread surface was rated as good to very good.
• the addition of calcium stearate reduced bending stiffness by up to 17%.
• the original tear forces, in particular the knot-pull breaking strength which is important for surgical sutures, could be increased by the addition of the carboxylic acid salt with respect to the violet industrial standard and markedly increased compared to non-dyed, non-additized polymer. At the same time, the flexural modulus could be reduced.
• the cycle time could be significantly reduced by adding calcium stearate to undyed PDO.
• the necessary Tied period between injection of the melt and ejection of the molding from the mold could be more than halved.
• Shaped bodies and threads made of undyed PDO polymer with anchoring structures in particular when the incisions and / or punches were made in the unstretched state and subsequently drawn, can be produced only after the addition of carboxylic acid salt in sufficient strength and without thread breaking during drawing.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Surgery (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Medicinal Chemistry (AREA)
• Dermatology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Engineering & Computer Science (AREA)
• Materials Engineering (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Composite Materials (AREA)
• Inorganic Chemistry (AREA)
• Medical Informatics (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Materials For Medical Uses (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47998475

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Citations (2)

Family Cites Families (11)

• 2012
  • 2012-04-18 DE DE102012206400A patent/DE102012206400A1/de not_active Ceased
• 2013
  • 2013-03-28 EP EP13712581.1A patent/EP2838576A1/de not_active Withdrawn
  • 2013-03-28 WO PCT/EP2013/056752 patent/WO2013156293A1/de active Application Filing
  • 2013-03-28 US US14/394,804 patent/US10124086B2/en not_active Expired - Fee Related
  • 2013-03-28 KR KR20147031971A patent/KR20150004380A/ko not_active Application Discontinuation

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events